Satisfaction with treatment: from the perspective of consumer, family and informal carers or professionals/carers at any point during the acute management stage · psychosis‐induced aggression or agitation
1 finding from 1 review
Economic outcomes: cost‐effectiveness ‐ clinically important · psychosis‐induced aggression or agitation
1 finding from 1 review
Global state: Average endpoint global state score (clinically improved) (no data) · patients with schizophrenia
1 finding from 1 review
Adverse effects ‐ important extrapyramidal adverse effects · patients with schizophrenia
It is very uncertain whether zuclopenthixol dihydrochloride changes adverse effects: Clinically important general adverse effect… compared with placebo (very low certainty).
1 finding from 1 review
Death: Suicide and natural causes (no data) · patients with schizophrenia
1 finding from 1 review
Length of hospital stay · patients with schizophrenia
1 finding from 1 review
Mental state: Average endpoint general mental state score (clinically improved) (no data) · patients with schizophrenia
1 finding from 1 review
General functioning: Average endpoint general functioning score (clinically improved) (no data) · patients with schizophrenia
1 finding from 1 review
Tranquilisation or asleep not asleep at 2 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes tranquillisation or asleep not asleep at 2 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · patients with psychosis‐induced aggression or agitation
HALOPERIDOL may leads to lower repeated need for tranquillisation needing additional injection… compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Specific behaviour ‐ threat or injury to self or others average change score (ABS, high = worse) at 2 hours · patients with psychosis‐induced aggression or agitation
1 finding from 1 review
Global outcome ‐ overall improvement (not any improvement) · patients with psychosis‐induced aggression or agitation
HALOPERIDOL showed no clear difference in global outcome ‐ overall improvement (not any improvement) compared with PLACEBO/NIL (low certainty).
1 finding from 1 review
Adverse effects: Specific ‐ dystonia during 24 hours · patients with psychosis‐induced aggression or agitation
It is very uncertain whether HALOPERIDOL changes adverse effects: Specific ‐ dystonia within 24 hours compared with PLACEBO/NIL (very low certainty).
1 finding from 1 review
Economic outcome ‐ not reported · patients with psychosis‐induced aggression or agitation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Global state: Clinically important change ‐ no improvement ‐ defined as PANSS < 50% reduction (short term) · patients with schizophrenia
WENDAN DECOCTION may leads to lower global state: Clinically important change ‐ no improvement ‐ defined… compared with PLACEBO OR NO TREATMENT (low certainty).
1 finding from 1 review
Mental state: clinically important change in mental state · patients with schizophrenia
1 finding from 1 review
Adverse effects: Clinically important decline, as defined by each study (short term) · patients with schizophrenia
1 finding from 1 review
Adverse effects: Metabolic ‐ weight change (medium term) · patients with schizophrenia
1 finding from 1 review
Quality of life/satisfaction with care: Clinically important change in quality of life/satisfaction, as defined by each study (medium term) · patients with schizophrenia
1 finding from 1 review
Economic outcomes: Costs due to treatment, as defined by each study (long term) · patients with schizophrenia
1 finding from 1 review